Incubation of Whole Blood at 39 C Augments Gamma Interferon (IFN- )-Induced Protein 10 and IFN- Responses to Mycobacterium tuberculosis Antigens

Similar documents
Effect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive Houston, Texas October 15-17, 2013

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

TB Intensive Tyler, Texas December 2-4, 2008

Technical Bulletin No. 172

TB Prevention Who and How to Screen

Identifying TB co-infection : new approaches?

Testing for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle

Investigation of false-positive results by the QuantiFERON-TB Gold In-Tube assay

ESCMID Online Lecture Library. by author

QuantiFERON-TB Gold Plus

Children in contact with adults with

Approaches to LTBI Diagnosis

Evaluation of an In Vitro Assay for Gamma Interferon Production in Response to Mycobacterium tuberculosis Infections

Peggy Leslie-Smith, RN

RESEARCH NOTE QUANTIFERON -TB GOLD IN-TUBE TEST FOR DIAGNOSING LATENT TUBERCULOSIS INFECTION AMONG CLINICAL-YEAR THAI MEDICAL STUDENTS

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Detecting latent tuberculosis using interferon gamma release assays (IGRA)

Diagnostic challenges of active childhood TB in Tanzania. Michala Vaaben Rose, MD, Ph.D Department of Infectious Diseases, Hvidovre

Making the Diagnosis of Tuberculosis

Supplementary webappendix

Using Interferon Gamma Release Assays for Diagnosis of TB Infection

Immediate Incubation Reduces Indeterminate Results for QuantiFERON-TB Gold In-Tube Assay

Didactic Series. Latent TB Infection in HIV Infection

Screening for Tuberculosis Infection. Harlingen, TX. Linda Dooley, MD has the following disclosures to make:

Interferon Gamma Release Assay Testing for Latent Tuberculosis Infection: Physician Guidelines

In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

Laboratory Updates on IGRA Testing

ORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients

staining and flow cytometry

Review. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Interferon- assays for tuberculosis diagnosis

Clinical Utility of the QuantiFERON TB-2G Test for Elderly Patients With Active Tuberculosis*

Comparison of Tuberculin Skin Test and New Specific Blood Test in Tuberculosis Contacts

2016 OPAM Mid-Year Educational Conference, Sponsored by AOCOPM Sunday, March 13, 2016

Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay

Conflict of Interest Disclosures:

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

Comparison of Quantiferon-TB Gold With Tuberculin Skin Test for Detecting Latent Tuberculosis Infection Prior to Liver Transplantation

Transmission and Pathogenesis of Tuberculosis

A Comparison of Interferon-g and IP-10 for the Diagnosis of Tuberculosis

Post-treatment change in Mycobacterium tuberculosis antigenstimulated tumor necrosis factor-alpha release in patients with active tuberculosis

Didactic Series. Latent TB Infection in HIV Infection

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

Received 21 August 2007/Returned for modification 14 September 2007/Accepted 11 November 2007

Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients

LTBI-Tuberculin skin test. T-Spot.TB Technology. QuantiFERON -TB Gold In Tube T-SPOT.TB ELISA ELISA

ORIGINAL ARTICLE /j x. and 3 Department of Internal Medicine, University of Tor Vergata, Rome, Italy

[DOI] /j.issn

CHAPTER 3: DEFINITION OF TERMS

Role of the Laboratory in TB Diagnosis and Management

More significance of TB- IGRA except for the diagnose of tuberculosis

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Thorax Online First, published on December 8, 2009 as /thx

Effect of tuberculin skin testing on a Mycobacterium tuberculosisspecific

Testing & Treatment for TB Infection: Blood Tests, Skin Tests, Who to Screen & Who to Treat?

Diagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis

Self-Study Modules on Tuberculosis

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

Mædica - a Journal of Clinical Medicine

Journal of Infectious Diseases Advance Access published August 2, 2013

The Use of Interferon-gamma Release Assays in HIV-positive Individuals

New NICE guideline updates recommendations for diagnosing latent tuberculosis

Qualitative and quantitative results of interferon-γ release assays for monitoring the response to anti-tuberculosis treatment

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

Dimitrios Vassilopoulos,* Stamatoula Tsikrika, Chrisoula Hatzara, Varvara Podia, Anna Kandili, Nikolaos Stamoulis, and Emilia Hadziyannis

Prevalence and risk factors of latent tuberculosis infection among health care workers in Malaysia

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Is the QuantiFERON-TB Blood Assay a Good Replacement for the Tuberculin Skin Test in Tuberculosis Screening? A Pilot Study at Berkshire Medical Center

Research Article Cytokines as Biomarkers in the Diagnosis of MDR TB Cases

TB Epidemiology. Richard E. Chaisson, MD Johns Hopkins University Center for Tuberculosis Research

TB Nurse Case Management Davenport, Iowa September 27 28, 2011

T-CELL RESPONSES ASSESSED USING IGRA AND TST ARE NOT CORRELATED WITH AFB GRADE AND CHEST RADIOGRAPH IN PULMONARY TUBERCULOSIS PATIENTS

International Journal of Innovative Research in Medical Science (IJIRMS)

Tuberculin Skin Test (TST) and Interferon-gamma Release Assays (IGRA)

Tuberculosis Tools: A Clinical Update

Update on TB Vaccines. Mark Hatherill South African TB Vaccine Initiative (SATVI) University of Cape Town

of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis

Madhukar Pai, MD, PhD Jessica Minion, MD

Diagnosis and Medical Case Management of Latent TB. Bryan Rock, MD April 27, 2010

Diagnosis Latent Tuberculosis. Disclosures. Case

Richard N. van Zyl-Smit 1, Rannakoe J. Lehloenya 1,2, Richard Meldau 1, Keertan Dheda 1,3,4. Introduction

Use of an Interferon- Release Assay To Diagnose Latent Tuberculosis Infection in Foreign-Born Patients*

(In-Tube Method) The Whole Blood IFN-gamma Test Measuring Responses to ESAT-6, CFP-10 & TB7.7(p.4) Peptide Antigens PACKAGE INSERT

Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Use of Interferon-γ Release Assays (IGRAs) in TB control in low and middle-income settings - EXPERT GROUP MEETING -

Adachi et al. SpringerPlus 2013, 2:440 a SpringerOpen Journal

The immunologic paradox in the diagnosis of

JCM Version 3. Utilization of the QuantiFERON-TB Gold Test in a 2-Step Process with the

Evidence-based use of the new diagnostic tools for TB-infection

The tuberculin skin test (TST) was until recently the

Communicable Disease Control Manual Chapter 4: Tuberculosis

Perspective in novel TB vaccine development Mohamed Ridha BARBOUCHE M.D., Ph.D. Department of Immunology Institut Pasteur de Tunis

TB Laboratory for Nurses

Author's response to reviews

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

Transcription:

CLINICAL AND VACCINE IMMUNOLOGY, July 2011, p. 1150 1156 Vol. 18, No. 7 1556-6811/11/$12.00 doi:10.1128/cvi.00051-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Incubation of Whole Blood at 39 C Augments Gamma Interferon (IFN- )-Induced Protein 10 and IFN- Responses to Mycobacterium tuberculosis Antigens Martine G. Aabye, 1 Pernille Ravn, 1,2 Isik S. Johansen, 3 Jesper Eugen-Olsen, 1 and Morten Ruhwald 1 * Clinical Research Centre, University of Copenhagen, Hvidovre Hospital, Copenhagen, Denmark 1 ; Unit of Infectious Diseases, University of Copenhagen, Herlev Hospital, Copenhagen, Denmark 2 ; and Department of Infectious Diseases, University of Southern Denmark, Odense Hospital, Odense, Denmark 3 Received 7 February 2011/Returned for modification 26 February 2011/Accepted 11 May 2011 A rarely challenged dogma in cell-mediated immune (CMI) assays is the incubation temperature, 37 C. Fever augments proinflammatory immune responses in vivo, and the aim of this study was to explore whether incubation at fever-range temperature could increase antigen-specific biomarker responses. We compared CMI responses following incubation of whole blood at 37 C and 39 C. Whole blood was obtained from (i) 34 healthy subjects whose blood was incubated with TB10.4 antigen, present in the Mycobacterium bovis bacillus Calmette- Guérin vaccine and many environmental mycobacteria; (ii) 8 TB patients and 8 controls incubated with Mycobacterium tuberculosis-specific antigens in the QuantiFERON-TB Gold test (QFT-IT); and (iii) from both groups incubated with a T cell mitogen. T cell responses (gamma interferon [IFN- ]) and responses from antigen-presenting cells (IFN- -induced protein 10 [IP-10]) were determined. We further evaluated the effect of adding interleukin-7 (IL-7) and blocking IL-10 during incubation. In TB patients, IFN- and IP-10 levels were increased 4.1- and 3.4-fold, respectively, at 39 C incubation (P < 0.001). Similar results were seen after mitogen stimulation. In subjects responding to TB10.4, the effects were less pronounced and significant only for IP-10. Incubation at 39 C increased IP-10 and IFN- responsiveness to both antigens and mitogen in persons with baseline or initial low responses. Adding IL-7 and blocking IL-10 augmented the effects in synergy with fever-range temperature. Incubation at fever-range temperature vividly increases CMI responsiveness to antigen stimulation in vitro in tuberculosis patients and may increase the sensitivity of CMI assays. Cell-mediated immune (CMI) assays are important research tools used to monitor T cell-dependent immune responses toward antigens from, e.g., pathogens or vaccines. CMI assays rely on generation of an in vitro immune response and quantification of the proinflammatory immune response (26). In clinical medicine, CMI assays are used for the diagnosis of infections that cannot be detected with direct methods (28). An example is the diagnosis of latent infection with Mycobacterium tuberculosis, where either purified peripheral blood mononuclear cells (PBMCs) or whole blood is incubated with M. tuberculosis-specific antigens, followed by quantification of the gamma interferon (IFN- ) response, hence the name IFN- release assays (IGRAs) (3). A rarely challenged dogma in CMI assays both in research and in diagnostic medicine is that the incubation temperature is optimal at 37 C. Fever is a part of the innate immune response in vivo and can aid the immune defense by impairing the viability of pathogens with strict temperature preferences or by enhancing immunological reactions (reviewed in reference 38). Previous studies indicate that fever-range temperature in vivo and in vitro augments antigen presentation and coreceptor expression and skews antigen-presenting * Corresponding author. Mailing address: Clinical Research Centre, University of Copenhagen, Hvidovre Hospital, Copenhagen 2650, Denmark. Phone: 45 61262623. Fax: 45 38623797. E-mail: mruhwald @gmail.com. Supplemental material for this article may be found at http://cvi.asm.org/. Published ahead of print on 25 May 2011. cells (APCs) toward activation, in concert with augmented T cell responsiveness and Th1 bias (5, 6, 17, 33). One of the major challenges of CMI assays and IGRAs, in particular is achieving a consistent and strong response (i.e., high sensitivity) without generating nonspecific immune activation (i.e., compromising specificity). We and others have demonstrated that, compared to T cell responses, the APCs interacting with the specific T cells generate stronger chemokine and cytokine signals that could enable simpler or more sensitive readouts of CMI assays (reviewed in reference 24). In several studies, the chemokine IFN- -induced protein 10 (IP-10) has shown promise as a novel marker for immunodiagnosis of infection with M. tuberculosis in both children and adults (1, 13, 15, 21 23, 30). In an attempt to further improve CMI assays, we hypothesized that incubation at fever-range temperatures in vitro could lead to an increase in proinflammatory immune responses and potentially an increase in the sensitivity of IGRA and CMI assays. Interleukin-7 (IL-7) is a cytokine that promotes survival of T cells (8, 9). IL-10 is an anti-inflammatory cytokine released by T cells and monocytes/macrophages with immune activation (25). Both IL-7 and blocking of IL-10 have previously been shown to augment IFN- responses to M. tuberculosis-specific antigens (9, 10, 12). The aim of this study was to explore if incubation of cells at fever-range temperature could potentiate biomarker responses in a simple whole-blood CMI assay and if IL-7 and anti-il-10 had an additional effect. Antigen-specific T cell responses were evaluated using IFN- as marker for a T cell response and the 1150

VOL. 18, 2011 39 C INCUBATION OF IGRA 1151 FIG. 1. Impact of incubation temperature on IFN- and IP-10 responsiveness. Whole blood was drawn and incubated 18 h at 20, 30, 37, 39, 41, and 43 C with a cocktail of peptides from the antigen TB10.4 (antigen; black circles) or with PBS (nil; white circles). Data shown are from one experiment with two representative donors (solid and dotted lines, respectively). Findings were reproduced for 11 additional donors. In some experiments, fewer temperatures were tested. chemokine IP-10 as a marker for the APC response. We assessed the effects in three models: (i) a TB10.4 antigen model detecting responses to antigens present in the Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine and other mycobacteria in healthy controls, (ii) a tuberculosis (TB) diagnostic model measuring responses to M. tuberculosisspecific antigens (early secretory antigenic target 6 [ESAT- 6], culture filtrate protein 10 [CFP-10], and TB7.7) in TB patients, and (iii) a model independent of antigen and infection using a T cell mitogen. (Extracts of the data in this paper were presented as an oral presentation at the European Respiratory Society s Annual Assembly in Barcelona, Spain, September 2010.) MATERIALS AND METHODS Setting and patient recruitment. The TB10.4 response study included healthy nurses and other employees with no history of TB exposure at the outpatient clinic at the Department of Infectious Diseases or at the Clinical Research Centre at Hvidovre Hospital, Copenhagen, Denmark. Information on BCG vaccination status was obtained from all individuals. The TB antigen study included patients with active TB as well as healthy controls. Blood was prospectively collected from patients suspected of having active TB attending the outpatient clinic at the Department of Infectious Diseases, Hvidovre Hospital, less than 7 days after they started treatment. Healthy controls consisting of employees at the Clinical Research Centre, Hvidovre Hospital, with no history of prior TB or TB exposure were included. Reagents and equipment. Peptide TB10.4 is a mix of 9 overlapping 18-mer peptides from TB10.4 that was diluted in phosphate-buffered saline (PBS) and used at a final concentration of 2.5 g/ml (JPT, Germany). TB10.4 (Rv0288) is expressed by several strains of the Mycobacterium tuberculosis complex, including M. tuberculosis and BCG, as well as M. kansasii, M. avium, M. intracellulare, and M. marinum (29). The QuantiFERON-TB Gold test (QFT-IT) tubes comprise a mix of 7 ESAT-6, 6 CFP-10, and 1 TB7.7 16- to 25-mer peptides used at a final concentration of 1 g/ml (16). Phytohemagglutinin (PHA) was used as the mitogen at a final concentration of 5 g/ml in the QFT-IT (16). Recombinant human IL-7 (2 ng/ml; R&D Systems) and monoclonal antibodies (MAbs) blocking human interleukin-10 (anti-il-10; 1 g/ml; MBL) were added before incubation. The contents of the QFT-IT tubes comprise dextrose as the nutrient (2 mg/ml) and were added to all other cultures. Concentrations of IL-7, anti-il-10, and dextrose were adopted from the literature (9, 10, 19). Blood collection and incubation for biomarker measurements. Whole blood was collected in 10-ml heparinized tubes (BD, United Kingdom). One milliliter of blood was added to the QFT-IT tubes and, for the TB10.4 study, to Nunc cryotubes (1.5 ml; Thermo Fisher Scientific, Denmark), optionally with IL-7 and anti-il-10. Blood was incubated in incubators, water baths, and heating blocks. An incubator was used for incubation at 37 C, while a water bath placed within an incubator was used for incubation at 39 C. All tubes were incubated with closed lids for precisely 18 h without addition of CO 2. Temperatures were measured using a mercury thermometer and were checked at least 4 times during each incubation at at least 2-h intervals and did not vary by more than 0.2 C. Measurements. Following incubation, IP-10 was measured in a 1:9 dilution using an in-house sandwich enzyme-linked immunosorbent assay (ELISA) with a linear range from 8 to 2,500 pg/ml. IFN- levels were measured using the QuantiFERON ELISA. To improve analytical precision, the standard curve was extended (with 8 IU/ml [400 pg/ml] and 16 IU/ml [800 pg/ml]); other standards were retained as per the manufacturer s protocol. In all other aspects, the manufacturer s instructions were followed. IP-10 levels are presented after multiplying by the dilution factor. In the data presented, background levels of biomarkers (nil) are subtracted. White blood cell counts were done at the Department of Clinical Biochemistry, Hvidovre Hospital (Cobas, Roche, Switzerland). Statistical analysis and result interpretation. Data were analyzed using SAS, version 9.2, software (SAS Institute) and two-sided nonparametric tests. A P value of 0.05 was considered significant. In TB patients and controls, IFN- values were converted to test results using the manufacturer s recommendations and software. Ethical considerations. Permission to conduct the study was obtained from the Ethical Committee of the Municipality of Copenhagen (KF-01-278477). All study participants gave written informed consent to participate. RESULTS Identification of optimal incubation temperature. Antigendependent IFN- and IP-10 responses after stimulation with TB10.4 increased with increasing temperature from 20 C, reaching a maximum at 39.5 C (Fig. 1). At 40 C, biomarker responses were lower in some (30%) of our samples, and most often the responses purged at 41 C. At the risk of underestimating the potential of fever-range incubation, we prioritized robustness and chose incubation at 39 C for the following studies. TB10.4 antigen study. A total of 34 donors, of whom half (17/34) were BCG vaccinated, were recruited. The donors were divided into 23 responders and 11 nonresponders on the basis of IP-10 responses above and below 500 pg/ml, respectively, after incubation of their blood with TB10.4 peptides at 37 C without additional stimulus (Fig. 2). Among responders and nonresponders, 65% (15/23) and 18% (2/11), respectively, were BCG vaccinated and 70% (7/23) and 82% (9/11), respectively, were female (P 0.68), and the median ages were 39 years (range, 26 to 54 years) and 30 years (range, 26 to 48 years) (P 0.09), respectively. In nonresponders, we found no significant differences in IFN- or IP-10 levels under any incubation conditions, and all

1152 AABYE ET AL. CLIN. VACCINE IMMUNOL. FIG. 2. Dividing donors into responders and nonresponders. IP-10 responses in plasma from 34 healthy donors ordered from lowest to highest responder. Whole blood was drawn and incubated for 18 h at 37 C with a cocktail of peptides from the antigen TB10.4. Donors who responded with 500 pg/ml IP-10 were considered TB10.4 responders. nonresponders had low IFN- and IP-10 responses at 37 C (Fig. 3A and 4A). Two nonresponders responded after incubation at 39 C by both IP-10 and IFN- production both with and without anti-il-10 and IL-7. These two donors were, as the only ones in the nonresponder group, BCG vaccinated. None of the other nonresponders had an increase in IFN- or IP-10 levels, regardless of incubation conditions. In responders, antigen-dependent IP-10 levels, but not IFN- levels, were significantly higher at 39 C than at 37 C (P 0.02 and P 0.41, respectively); the median fold changes were 1.3 (range, 0.3 to 4.1) for IP-10 and 1.0 (range, 0.6 to 2.4) for IFN- (Fig. 3B and 4B). Adding anti-il-10 and IL-7 gave higher levels of IP-10 and IFN- at both 37 and 39 C (P 0.001 for all); median fold IFN- increases were 1.3 (range, 0.8 to 7.8) and 2.5 (range, 1.3 to 21.8), respectively, after adding anti-il-10 or IL-7; and for IP-10, the fold increases were 1.4 (range, 1.0 to 3.1) and 1.8 (range, 0.9 to 4.6), respectively. IL-7 alone increased IFN- responsiveness at both 37 C and 39 C, but IP-10 was increased only at 39 C. There was no significant effect of blocking IL-10 alone. The effects of adding IL-7 or anti-il-10 MAbs separately at 37 C and 39 C are shown in Fig. S1 and S2 in the supplemental material. The combined effect of increased incubation temperature and anti-il-10 and IL-7 was synergistically augmenting for both IP-10 (P 0.0001) and IFN- (P 0.01); i.e., the effect of the two interventions used together was greater than addition of the effect of each intervention used separately (data not shown). Two responders with consistently high IP-10 responses to TB10.4 antigens under all incubation conditions ( 500 pg/ml) had low IFN- responses when their blood was incubated at 37 C. Incubation at 39 C both with and without anti-il-10 and IL-7 brought IFN- responses in these two donors as well (Fig. 3B). TB antigen study. For the TB diagnosis study, 8 TB patients and 8 healthy controls were recruited. Among the TB patients, the median age was 43 years (range, 25 to 60 years) and 38% (3/8) were female. Six were from regions where TB is endemic and two were from Scandinavia. Six patients had culture-confirmed pulmonary TB; one had nucleic acid amplification test (NAAT)-confirmed TB spondylitis; and one was diagnosed with TB meningitis on the basis of a positive tuberculin skin test (35 mm), cerebrospinal fluid pleocytosis, and characteristic magnetic resonance imaging findings, while NAAT and culture results were negative. Among controls, 3 were female (38%) and the median age was 36 years (range, 27 to 45 years). There were no significant differences between TB patients and controls in gender distribution (38% [3/8] and 38% [3/8] female, respectively; P 1.00) or age (median, 43 years [range, 25 to 60 years] and 36 years [range, 27 to 45 years], respectively; P 0.09). Among controls, there was no significant difference in IP-10 or IFN- responses to the antigens when incubation was at 39 C with or without anti-il-10 and IL-7 compared to those at 37 C (Fig. 5A and 6A). In TB patients, antigen-dependent IP-10 and IFN- levels were increased at 39 C (P 0.01 for all), especially when anti-il-10 and IL-7 were added (P 0.001 for all) (Fig. 4B and 5B). The effects of fever-range incubation temperature were comparable for both biomarkers: for 37 C versus 39 C, median fold changes were 4.1 (range, 1.6 to 8.1) for IFN- versus 3.5 (range, 1.4 to 8.1) for IP-10 (P 0.95); for 37 C versus 39 C with IL-7 and anti-il-10, median fold changes were 6.4 (range, 0 to 21.6) for IFN- and 3.5 (range, 1.5 to 25) for IP-10 (P 0.95). The increase in IP-10 and IFN- responses at the 39 C incubation temperature was significantly more pronounced in FIG. 3. IFN- responses to peptides from TB10.4 at 37 C and 39 C, with and without IL-7 and blockage of IL-10. (A) Data from 11 TB10.4 nonresponders; (B) data from 23 TB10.4 responders. Whole blood was drawn and incubated for 18 h at 37 C or 39 C in the presence or absence of IL-7 and blocking antibodies to IL-10 (denoted plus ). For all values, the levels in the unstimulated sample were subtracted. **, P 0.001 compared to 37 C.

VOL. 18, 2011 39 C INCUBATION OF IGRA 1153 FIG. 4. IP-10 responses to peptides from TB10.4 at 37 C and 39 C, with and without IL-7 and blockage of IL-10. (A) Data from 11 TB10.4 nonresponders; (B) data from 23 TB10.4 responders. Whole blood was drawn and incubated for 18 h at 37 C or 39 C in the presence or absence of IL-7 and blocking antibodies to IL-10 (denoted plus ). For all values, the levels in the unstimulated sample were subtracted. **, P 0.001 compared to 37 C. TB patients responding to the TB antigens than in healthy individuals responding to TB10.4 antigens (P 0.001 for both). There were no significant differences in background (nil) release of IFN- levels after incubation at 37 C and 39 C without anti-il-10 and IL-7 (median, 0.14 IU/ml versus 0.08 IU/ml [P 0.14]) and with anti-il-10 and IL-7 (median, 0.14 IU/ml versus 0.26 IU/ml [P 0.08]) (data not shown). Nil IP-10 levels were similar when incubation was at 37 C and 39 C (median, 620.0 pg/ml versus 620.6 pg/ml [P 0.58]), but they were higher when anti-il-10 and IL-7 were added (620.0 pg/ml versus 2,740 pg/ml [P 0.01]) (graphs not shown). For both biomarkers, responsiveness to mitogen stimulation was increased at 39 C compared to that at 37 C (P 0.01), with median 3.8-fold (range, 1.0- to 100.3-fold) changes for IFN-, compared to median 1.4-fold (range, 1.0- to 1,979.0- fold) changes for IP-10 (P 0.127) (Fig. 7). The effect of fever-range temperature was further increased when anti- IL-10 and IL-7 (P 0.001) were added. Importantly, the effects were especially pronounced in the patients with the lowest responses to mitogen stimulation. Effects of fever-range incubation temperature and IL-7 plus anti-il-10 on sensitivity of QFT-IT. At the standard 37 C incubation temperature, all controls were QFT-IT negative. Six of 8 TB patients were QFT-IT positive and 2 patients with culture-confirmed TB had indeterminate results, on the basis of low IFN- levels in the mitogen sample: one patient converted to QFT-IT positive at the 39 C incubation temperature, with increases in antigen-dependent IFN- levels from 0.25 to 2.00 IU/ml and mitogen-induced IFN- levels from 0.17 to 11.00 IU/ml; the other converted from indeterminate to a (false) negative result, with an increase in mitogen-induced IFN- levels from 0.25 to 7.49 IU/ml, but maintained a low antigen-dependent IFN- response (0.00 to 0.12 IU/ml). We have no previous set cutoff for IP-10 as a diagnostic marker for TB using the ELISA, so no firm conclusion can be drawn, but we observed a pattern for IP-10 similar to that for IFN-. At 39 C, there was a complete segregation between TB patients and controls using an IP-10 cutoff in the range of 2,050 to 3,100 pg/ml. When incubation was at 39 C with anti-il-10 and IL-7, two controls had an increase in antigen-dependent IFN- and IP-10 levels, and one of these controls converted to QFT-IT positive. DISCUSSION Summary of major findings. This study shows that incubation at fever-range temperature augments cell-mediated immune responses. In three different models, we demonstrate that T cell IFN- and monocyte IP-10 responses are increased at a 39 C incubation temperature. In addition, we found that the CMI responses were further augmented by the addition of the T cell survival cytokine IL-7 and neutralizing antibodies against the anti-inflammatory cytokine IL-10. Finally, we ob- FIG. 5. IFN- responses to M. tuberculosis-specific antigen stimulation at 37 C, 39 C, and 39 C with IL-7 and blockage of IL-10. Whole blood was drawn and incubated 18 h at 37 C or 39 C and at 39 C with IL-7 and blocking antibodies to IL-10 (denoted plus ). One milliliter of whole blood from 8 controls (A) and 8 TB patients (B) was stimulated with overlapping peptides specific for M. tuberculosis using QFT-IT tubes. For all values, the levels in the unstimulated sample were subtracted. *, P 0.01 compared to 37 C; **, P 0.001 compared to 37 C.

1154 AABYE ET AL. CLIN. VACCINE IMMUNOL. FIG. 6. IP-10 responses to M. tuberculosis-specific antigen stimulation at 37 C, 39 C, and 39 C with IL-7 and blockage of IL-10. Whole blood was drawn and incubated 18 h at 37 C or 39 C and at 39 C with IL-7 and blocking antibodies to IL-10 (denoted plus ). One milliliter of whole blood from 8 controls (A) and 8 TB patients (B) was stimulated with overlapping peptides specific for M. tuberculosis using QFT-IT tubes. For all values, the levels in the unstimulated sample were subtracted. *, P 0.01 compared to 37 C; **, P 0.001 compared to 37 C. served that incubation at fever-range temperatures could bring low responders and nonresponders to respond with high levels of both IP-10 and IFN-. Results in light of previous studies. Fever is a physiological reaction when the immune system combats invading microorganisms; therefore, it is intuitively appealing that the proinflammatory reaction in vitro would be more potent if it is done under conditions simulating the in vivo situation. While incubation under both hypothermic temperature (below 37 C) and heat shock temperature (41 to 43 C) conditions have been shown to impair immune cell function (18, 27, 35, 37), a number of studies suggest that incubation at fever-range temperatures (38 to 41 C) can augment the responsiveness of murine and human immune cells compared to that at the conventional 37 C incubation: at fever-range temperatures, stimulated PBMCs have been shown to increase antigen presentation and activity of APCs and to augment T cell responses to mitogen stimulation (5, 17, 33, 38). The production of mainly Th1-specific proinflammatory cytokines, e.g., IFN-, tumor necrosis factor alpha, IL-1, and IL-2, has been found to increase with incubation at fever-range temperatures, while the production of others, mainly Th2-specific cytokines such as IL-10, is downregulated (4, 5, 14, 38). Previous studies have primarily been carried out in PBMC cultures stimulated with mitogens or whole bacteria and never in a simple whole-blood assay. To our knowledge, this is the first study to show that fever-range incubation temperature can augment the antigen-specific responses to peptide stimulation in both T cells and monocytes in vitro. Effects of adding and blocking cytokines. Previous studies have demonstrated that adding IL-7 or blocking IL-10 can augment M. tuberculosis-specific antigen responsiveness in vitro (9, 10, 12). In the TB10.4 study, we compared anti-il-10 and IL-7 head-to-head and found that the effects of added IL-7 appeared to be superior to those of anti-il-10 alone. IL-7 functions as a survival cytokine for T cells, and the effects of IL-7 were more pronounced when incubation was at higher temperature, where cells are likely to be under more stress (8). In contrast to the bovine data from Denis et al (9), we were not able to demonstrate an effect in IFN- responses of anti-il-10 added alone. Can fever-range incubation temperature improve IGRAs? Incubation at 39 C did not seem to compromise specificity in either the TB10.4 or the TB diagnostic model. On the contrary, the 39 C incubation temperature led to better separation between responders/nonresponders and patients/controls, suggesting that it might reduce the phenomenon of IGRA converters and reverters (7, 32, 34). Incubation at 39 C converted the only two BCG-vaccinated TB10.4 nonresponders to strong responders by both IFN- and IP-10 as well as one TB patient from an indeterminate to a positive QFT-IT result. This suggests that incubation at 39 C might increase assay sensitivity. While adding anti-il-10 and IL-7 further added to this differentiation, it caused one control to convert to a false-positive FIG. 7. IFN- and IP-10 responses to mitogen stimulation at 37 C, 39 C, and 39 C with IL-7 and blockage of IL-10. One milliliter of whole blood from 8 controls and 8 TB patients was stimulated with mitogen in the QFT-IT mitogen tube and incubated 18 h at 37 C or 39 C and at 39 C with IL-7 and blocking antibodies to IL-10 (denoted plus ). (A) Mitogen-induced IFN- concentrations; (B) mitogen-induced IP-10 responses. For all values, the levels in the unstimulated sample were subtracted. *, P 0.01 compared to 37 C; **, P 0.001 compared to 37 C.

VOL. 18, 2011 39 C INCUBATION OF IGRA 1155 QFT-IT result. Furthermore, while background IFN- levels were not affected, incubation at 39 C increased background IP-10 levels, although only in individuals with very strong antigen responses as well. Larger studies are needed in order to confirm whether incubation at fever-range temperatures can improve IGRA performance. Differences between vaccine responses and infection. An interesting observation was that incubation at fever-range temperatures seemed to have a greater effect in patients with an ongoing infection. This might be due to the fact that the TB10.4 response in healthy individuals is likely to derive mainly from central memory T cells (2, 11), whereas the TB antigen responses in patients with ongoing infection is derived from effector memory T cells (20, 31, 36). However, this study does not shed light on the exact mechanisms underlying the findings. Limitations. In our preliminary studies, we identified 39.5 C to be superior to 39 C. However, as we observed a negative effect in some of the patients and donors at incubation temperatures of 40 C, we choose 39 C to get a stable system. Further studies in the 38 to 40 C range are needed to dissect the truly optimal temperature point and hereby the full potential of the findings described in this report. Although the observed effects of incubation at fever-range temperatures were consistent, a larger sample size, especially the inclusion of more TB patients, is needed in order to substantiate these findings and assess the effect on diagnostic assays. Perspectives and conclusions. With this study, we present proof of principle of a simple no-cost method by which immunoassays commonly used for both diagnostic tests and research might be improved. Incubation at fever-range temperatures appears to be superior to the standard 37 C incubation temperature for both peptide antigen-dependent and mitogeninduced biomarker production. Adding IL-7 and anti-il-10 MAbs seems to augment the effects, but the findings suggest a potential compromise in specificity. This compromise might be justified, e.g., in children and patients with advanced HIV infection, patient groups in which the established tests perform poorly. Further studies with larger groups are needed to assess the diagnostic potential of these findings. It is at present unclear if the increased complexity and cost of the IGRA and CMI assay with increasing temperatures and adding and blocking cytokines is justified by improvements in diagnostic accuracy. ACKNOWLEDGMENTS Funding for this study was received from the Lundbeck Foundation, Capital Region of Copenhagen, the Danish Ministry of Science and Technology, the Danish Lung Association, the Medical Society of Copenhagen, and the Aase and Ejnar Danielsen Foundation. M.G.A., P.R., J.E.-O., and M.R. are registered as inventors on issued and pending patents filed by Hvidovre Hospital disclosing IP-10 as a biomarker for infection with M. tuberculosis. M.G.A. codesigned the study, included controls, performed the laboratory work, analyzed the data, and wrote the first draft of the manuscript. P.R. participated in the analysis and design of the study and coauthored the manuscript. I.S.J. included patients and compiled the clinical database. J.E.-O. supervised the laboratory work and analysis of the data. M.R. conceived the idea, codesigned the study, included controls, supervised the laboratory work and data analysis, and coauthored the manuscript. All authors have read and approved the final draft of the manuscript. REFERENCES 1. Aabye, M. G., et al. 2010. Potential of interferon-gamma-inducible protein 10 in improving tuberculosis diagnosis in HIV-infected patients. Eur. Respir. J. 36:1488 1490. 2. Andersen, P., and T. M. Doherty. 2005. The success and failure of BCG implications for a novel tuberculosis vaccine. Nat. Rev. Microbiol. 3:656 662. 3. Andersen, P., M. E. Munk, J. M. Pollock, and T. M. Doherty. 2000. Specific immune-based diagnosis of tuberculosis. Lancet 356:1099 1104. 4. Bae, J., et al. 2007. Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J. Immunol. 178:7730 7737. 5. Basu, S., and P. K. Srivastava. 2003. Fever-like temperature induces maturation of dendritic cells through induction of hsp90. Int. Immunol. 15:1053 1061. 6. Bouchama, A., M. M. Hammami, E. Al Shail, and E. De Vol. 2000. Differential effects of in vitro and in vivo hyperthermia on the production of interleukin-10. Intensive Care Med. 26:1646 1651. 7. Cellestis. 2009. QuantiFERON-TB Gold: precision and reproducibility report. Cellestis, Carnegie, Australia. 8. Chetoui, N., M. Boisvert, S. Gendron, and F. Aoudjit. 2010. Interleukin-7 promotes the survival of human CD4 effector/memory T cells by upregulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology 130:418 426. 9. Denis, M., et al. 2007. Enhancement of the sensitivity of the whole-blood gamma interferon assay for diagnosis of Mycobacterium bovis infections in cattle. Clin. Vaccine Immunol. 14:1483 1489. 10. Feske, M., et al. 2008. Enhancement of human antigen-specific memory T-cell responses by interleukin-7 may improve accuracy in diagnosing tuberculosis. Clin. Vaccine Immunol. 15:1616 1622. 11. Goldsack, L., and J. R. Kirman. 2007. Half-truths and selective memory: interferon gamma, CD4( ) T cells and protective memory against tuberculosis. Tuberculosis (Edinb.). 87:465 473. 12. Jennes, W., L. Kestens, D. F. Nixon, and B. L. Shacklett. 2002. Enhanced ELISPOT detection of antigen-specific T cell responses from cryopreserved specimens with addition of both IL-7 and IL-15 the Amplispot assay. J. Immunol. Methods 270:99 108. 13. Kabeer, B. S., R. Sikhamani, and A. Raja. 2010. Comparison of interferon gamma and interferon gamma-inducible protein-10 secretion in HIV-tuberculosis patients. AIDS 24:323 325. 14. Kida, Y., et al. 2006. Increased liver temperature efficiently augments human cellular immune response: T-cell activation and possible monocyte translocation. Cancer Immunol. Immunother. 55:1459 1469. 15. Lighter, J., M. Rigaud, M. Huie, C. H. Peng, and H. Pollack. 2009. Chemokine IP-10: an adjunct marker for latent tuberculosis infection in children. Int. J. Tuberc. Lung Dis. 13:731 736. 16. Mori, T., et al. 2004. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am. J. Respir. Crit. Care Med. 170:59 64. 17. Ostberg, J. R., and E. A. Repasky. 2006. Emerging evidence indicates that physiologically relevant thermal stress regulates dendritic cell function. Cancer Immunol. Immunother. 55:292 298. 18. Roberts, N. J., Jr., and R. T. Steigbigel. 1977. Hyperthermia and human leukocyte functions: effects on response of lymphocytes to mitogen and antigen and bactericidal capacity of monocytes and neutrophils. Infect. Immun. 18:673 679. 19. Rothel, J., S. Wild, and A. Cosgriff. March 2009. Diagnostic assay for measuring a cell mediated immune response. Patent WO2004/042396. 20. Rueda, C. M., N. D. Marin, L. F. Garcia, and M. Rojas. 2010. Characterization of CD4 and CD8 T cells producing IFN-gamma in human latent and active tuberculosis. Tuberculosis (Edinb.). 90:346 353. 21. Ruhwald, M., M. Bjerregaard-Andersen, P. Rabna, J. Eugen-Olsen, and P. Ravn. 2009. IP-10, MCP-1, MCP-2, MCP-3, and IL-1RA hold promise as biomarkers for infection with M. tuberculosis in a whole blood based T-cell assay. BMC Res. Notes 2:19. 22. Ruhwald, M., et al. 2007. CXCL10/IP-10 release is induced by incubation of whole blood from tuberculosis patients with ESAT-6, CFP10 and TB7.7. Microbes Infect. 9:806 812. 23. Ruhwald, M., et al. 2008. Evaluating the potential of IP-10 and MCP-2 as biomarkers for the diagnosis of tuberculosis. Eur. Respir. J. 32:1607 1615. 24. Ruhwald, M., and P. Ravn. 2009. Biomarkers of latent TB infection. Expert Rev. Respir. Med. 3:387 401. 25. Sabat, R., et al. 2010. Biology of interleukin-10. Cytokine Growth Factor Rev. 21:331 344. 26. Sallusto, F., A. Lanzavecchia, K. Araki, and R. Ahmed. 2010. From vaccines to memory and back. Immunity 33:451 463. 27. Schiller, I., et al. 2009. Optimization of a whole-blood gamma interferon assay for detection of Mycobacterium bovis-infected cattle. Clin. Vaccine Immunol. 16:1196 1202. 28. Sester, M., et al. 2011. Interferon-gamma release assays for the diagnosis of active tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 37:100 111. 29. Skjot, R. L., et al. 2002. Epitope mapping of the immunodominant antigen

1156 AABYE ET AL. CLIN. VACCINE IMMUNOL. TB10.4 and the two homologous proteins TB10.3 and TB12.9, which constitute a subfamily of the esat-6 gene family. Infect. Immun. 70:5446 5453. 30. Syed Ahamed, K. B., B. Raman, A. Thomas, V. Perumal, and A. Raja. 2010. Role of QuantiFERON-TB gold, interferon gamma inducible protein-10 and tuberculin skin test in active tuberculosis diagnosis. PLoS One 5:e9051. 31. Tapaninen, P., A. Korhonen, L. Pusa, I. Seppala, and T. Tuuminen. 2010. Effector memory T-cells dominate immune responses in tuberculosis treatment: antigen or bacteria persistence? Int. J. Tuberc. Lung Dis. 14:347 355. 32. Tavast, E., E. Salo, I. Seppala, and T. Tuuminen. 2009. IGRA tests perform similarly to TST but cause no adverse reactions: pediatric experience in Finland. BMC Res. Notes 2:9. 33. Tournier, J. N., et al. 2003. Fever-like thermal conditions regulate the activation of maturing dendritic cells. J. Leukoc. Biol. 73:493 501. 34. Tuuminen, T., E. Tavast, R. Vaisanen, J. J. Himberg, and I. Seppala. 2010. Assessment of imprecision in gamma interferon release assays for the detection of exposure to Mycobacterium tuberculosis. Clin. Vaccine Immunol. 17:596 601. 35. van Bruggen, I., T. A. Robertson, and J. M. Papadimitriou. 1991. The effect of mild hyperthermia on the morphology and function of murine resident peritoneal macrophages. Exp. Mol. Pathol. 55:119 134. 36. Wang, X., et al. 2010. Association of mycobacterial antigen-specific CD4( ) memory T cell subsets with outcome of pulmonary tuberculosis. J. Infect. 60:133 139. 37. Yoshioka, H., et al. 1990. The influence of hyperthermia in vitro on the functions of peritoneal macrophages in mice. Jpn. J. Surg. 20:119 122. 38. Zhang, H. G., K. Mehta, P. Cohen, and C. Guha. 2008. Hyperthermia on immune regulation: a temperature s story. Cancer Lett. 271:191 204.